InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,236.01
(
-0.01%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: jq1234 post# 151308

Friday, 10/26/2012 5:02:27 PM

Friday, October 26, 2012 5:02:27 PM

Post# of 252302
Aren't overlapping patients??? Sure that's possible but I think it is far more likely that the TKI failures are from the T315I mutation against which imatinib, nilotinib, and dasatinib are ineffective. The reason I suspect this is that Teva ran a T315I trial and got a 23% response rate (along with some nasty side effects).
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up